Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report)'s share price traded down 6.5% during mid-day trading on Tuesday . The company traded as low as C$4.39 and last traded at C$4.60. 231,189 shares changed hands during mid-day trading, an increase of 52% from the average session volume of 152,449 shares. The stock had previously closed at C$4.92.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 target price for the company in a research report on Wednesday, January 8th. Leede Financial upgraded shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research note on Wednesday, January 22nd. Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Friday, January 17th. Stifel Nicolaus raised their target price on Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research report on Tuesday, January 14th. Finally, Alliance Global Partners upgraded Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. One analyst has rated the stock with a buy rating and five have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Strong Buy" and a consensus price target of C$5.58.
Check Out Our Latest Report on Medexus Pharmaceuticals
Medexus Pharmaceuticals Stock Performance
The stock has a market capitalization of C$97.87 million, a P/E ratio of 79.80 and a beta of 1.96. The business has a 50 day simple moving average of C$3.33 and a 200-day simple moving average of C$2.75.
Medexus Pharmaceuticals Company Profile
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
